Skip to main content
CLOV logo

CLOV · Clover Health Investments, Corp.

Track CLOV — free
$3.77 -0.40 (-9.59%) At close · Nov 19
Market Cap
$2.02B
Shares
535.42M
Volume · Nov 19 8.34M Avg daily vol (3M) 4.42M

Price & Indicators

 

Key stats

Close
$3.77
Open
$4.24
Day range
$3.76–4.30
52-week closing range
$1.70–5.41
Average volume, 30 days
4.9M
Short interest
23.0M · 4.3% of shares · 6.7 days
Short volume, last session
51%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Nov 6
Price history
Jun 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 16
Current report 8-K
Clover Health targets 2028 earnings opportunity and 2026 SG&A improvement

Clover Health targets a meaningful earnings opportunity through 2028 and expects full-year 2026 Adjusted SG&A ratio improvement of 100–150 basis points year over year. It reported ~159k members at the end of 3Q26 and offered no formal 2027 or 2028 guidance.

Regulation FD disclosure
5 source passages
Clover Health (Nasdaq: CLOV) Third Quarter 2026 Supplemental Q&A November 16, 2026 What we have shared is a meaningful earnings opportunity through 2028, built on the growth and clinical investments we've already made. That gives us a concrete foundation for discussing the opportunity without providing formal 2027 or 2028 guidance. We reiterated during 3Q26 earnings that we expect to meet or exceed our initial target of 100–150 basis points of improvement year over year for the full year 2026, while continuing to invest in CA, clinical capabilities, quality, Counterpart Health, and readiness for anticipated 2027 growth. While we’ve grown significantly, we’re still subscale relative to the large MA plans, with ~159k members at the end of 3Q26. Open the document at this passage
Nov 9
Investor event
2027 growth expected to drive substantial margin expansion

Clover Health expects another strong year of membership growth in 2027, with cohort maturation and Clover Assistant coverage supporting substantial margin expansion; year-to-date adjusted EBITDA reached $97 million and net income $62 million.

5 source passages
With us today, we have Clover Health and Clay Thornton, the newly appointed CFO So on a year-to-date basis, we've now delivered $97 million of adjusted EBITDA, $62 million of net income. We've got another strong year of growth coming in 2027. Our model really comes down to that, cohort maturation powered by Clover Assistant we'll have substantial margin expansion. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue growth turns nine-month results profitable

Clover Health Investments, Corp. reported nine-month revenue of $2,251.7 million, up 57%, and net income of $61.8 million versus prior-year losses. Adjusted EBITDA rose to $97.2 million, while cash, cash equivalents, and investments totaled $512.6 million at September 30, 2026.

Revenue $759.3M ▲ 52.9% Net income $6.44M Diluted EPS $0.01
Read from the MD&A section
5 source passages
Total revenues increased 53% to $759.3 million for the three months ended September 30, 2026, and 57% to $2,251.7 million for the nine months ended September 30, 2026, compared to the respective prior-year periods, driven primarily by growth in our Medicare Advantage membership and higher per-member premium. We reported net income of $6.4 million and $61.8 million for the three and nine month periods, respectively, compared to losses in the prior-year periods. Adjusted EBITDA increased to $97.2 million for the nine months ended September 30, 2026, from $45.0 million in the prior-year period. We continued to maintain a strong liquidity position, with cash, cash equivalents, and investments of $512.6 million at September 30, 2026. At September 30, 2026 and December 31, 2025, total cash, cash equivalents, and investments for the parent company, Clover Health Investments, Corp., and unregulated subsidiaries were $153.3 million and $122.0 million, respectively. Open the document at this passage
Nov 4
Current report 8-K Events of Nov 2
Third-quarter net income reaches $6 million; guidance improves

Clover Health Investments, Corp. reported third quarter 2026 GAAP net income of $6 million and raised full-year guidance to $2.97 billion - $3.00 billion revenue, $25 million - $35 million net income and $75 million - $85 million Adjusted EBITDA.

Financial results, Director or officer change, or executive pay
6 source passages
Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the third quarter 2026. Third quarter 2026 GAAP Net Income of $6 million, an improvement of $31 million year-over-year Improved Full Year 2026 Guidance: Total revenues | $2.97 billion - $3.00 billion GAAP Net income | $25 million - $35 million Adjusted EBITDA(4) | $75 million - $85 million Open the document at this passage
Oct 9
Current report 8-K Events of Oct 8
Regulation FD disclosure

CMS awarded Clover Health Investments, Corp. PPO plans 5 Stars and its HMO plan 4.5 Stars for 2027, affecting payment year 2028. CMS excluded 20 measures under appealed court decision; including them would have given the PPO plans 4.5 Stars.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.74B
Trailing 12 months
Net income (TTM)
$12.45M
Trailing 12 months
Revenue growth YoY
+52.9%
Year over year
Operating margin
0.5%
Trailing 12 months
P / E (TTM)
162.1
Trailing earnings · reciprocal yield 0.6%
FCF yield
6.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$268.07M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.7%
Year over year · more shares
Price change (1Y)
+62.5%
Trailing year
Short interest
4.3%
Latest settlement · 6.7 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Clover Health reported 48% Medicare Advantage membership growth alongside $28M Q2 GAAP net income, raised full-year 2026 guidance across all metrics citing strong cohort maturation, and signaled increasing confidence in 2027 supported by a 4.5-star payment year.

Bullish
  • + Raised full-year 2026 guidance across all metrics including revenue, gross profit, Adjusted EBITDA, GAAP net income and membership
  • + Medicare Advantage membership grew 48% year-over-year in Q2 with $743M revenue up 56%
  • + Achieved $28M Q2 GAAP net income and $41M Adjusted EBITDA, both materially improved year-over-year
  • + 4.5-star payment year confirmed following court ruling, providing additional flexibility for 2027 bids
  • + Adjusted SG&A improved ~220 bps as a percent of revenue, demonstrating operating leverage at scale
Bearish
  • − CMS has appealed the district court ruling on star rating recalculation, creating uncertainty around the 4.5-star outcome
  • − Company expects a typical seasonal Q4 adjusted EBITDA loss after positive Q3
  • − Outpatient utilization trends remain elevated from prior years despite moderation from March peak

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg −18%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 56%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −20%
trailing
6-month return −4%
trailing
YTD return +60%
this year
Relative strength +2%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +42 funds added
Insider flow Distributing
Net -$213.0K over 90 days · 100% sells
Short interest Falling
4.30% of shares out · ▼ -11.3% MoM · 6.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
231 holders — near 3-yr high, broad support
Squeeze score 53
elevated · 0–100
Fundamentals
Excellent
Revenue growth +40%
Y/Y
Gross margin 13%
expanding
EPS growth +38%
Y/Y
Free cash flow $-69.0M
Buyback $20.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 62%
annualized · 1-yr
Max drawdown −40%
past year
ATR 8.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 1 of last 2
Latest guidance · from the 8-K filed Nov 4, 2026
Total revenues · Full Year 2026 Raised $2.97B – $3B
Aug 5, 2026 $2.92B – $3B changed to Nov 4, 2026 $2.97B – $3B
prior FY $1.92B midpoint +55.1% Y/Y
GAAP Net Income · Full Year 2026 Raised $25M – $35M
Aug 5, 2026 $20M – $35M changed to Nov 4, 2026 $25M – $35M
Adjusted EBITDA profitability · Full Year 2026 $75M – $85M
Consolidated Gross Profit · Full Year 2026 Raised $540M – $555M
Aug 5, 2026 $525M – $555M changed to Nov 4, 2026 $540M – $555M
Previous outlook earlier release · from the 8-K filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Consolidated Gross profit · Full Year 2026 $525M – $555M
Adjusted EBITDA · Full Year 2026 $70M – $85M
Guided vs delivered · last 2 settled
Total revenues Full-year 2022
guided $3B – $3.4B
$1.1B Miss −65.7%
Total revenues full-year 2021
guided $1.42B – $1.47B
$1.47B Beat +1.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
−18% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
56% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +42 funds added
Insider flow Distributing
Net -$213.0K over 90 days · 100% sells
Short interest Falling
4.30% of shares out · ▼ -11.3% MoM · 6.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
231 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $4 · 56% Range high $5
vs 200-day avg +2% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Net income non-GAAP $40.35M Three Months Ended June 30, 2026 filing —
Insurance Benefits Expense Ratio 87.6% Three Months Ended June 30, 2026 filing —
Net medical claims incurred per member $1,254 the three months ended June 30, 2026 filing —
Adjusted EBITDA non-GAAP $81.2M Six Months Ended June 30, 2026 —
Adjusted Net income (non-GAAP) non-GAAP $80.09M Six Months Ended June 30, 2026 —
Adjusted SG&A (non-GAAP) non-GAAP $231.37M Six Months Ended June 30, 2026 —
Adjusted SG&A as a % of Total revenues non-GAAP 15.5% Six Months Ended June 30, 2026 —
Average Medicare Advantage membership 155,723 Six Months Ended June 30, 2026 —
Consolidated Gross profit (non-GAAP) non-GAAP $312.54M Six Months Ended June 30, 2026 —
Insurance Benefits Expense (non-GAAP) non-GAAP 1.29B Six Months Ended June 30, 2026 —
Insurance BER non-GAAP 87.1% Six Months Ended June 30, 2026 —
Insurance Segment gross profit $256.53M Six Months Ended June 30, 2026 —
Lives under Clover Management - Insurance members 157,309 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Healthcare Plans — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLOV
Clover Health Investments, Corp.
this stock
$2.02B +60.4% +40.3% — 4.3%
UNH
Unitedhealth Group Inc
$296.12B +0.1% +11.8% 18.9 1.6%
CVS
CVS HEALTH Corp
$102.41B +0.9% +7.8% 9.3 1.4%
ELV
Elevance Health, Inc.
$84.30B +11.3% +12.5% 16.6 2.1%
CI
Cigna Group
$71.95B -0.8% +11.2% 12.1 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
231
% held
29.3%
Net QoQ
+11.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
157
View
Short & Settlement
Short Interest Falling
Shares short
23.0M
Days to cover
6.7d
Change
-2.9M sh
View
Short Volume
Short vol %
51%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
26
Value
$120
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
47.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$213.0K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$1.9B
Net income (FY)
$-85.5M
EPS diluted
$-0.44
View
Buybacks
Authorized
$20.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
32

Clover Health targets a meaningful earnings opportunity through 2028 and expects full-year 2026 Adjusted SG&A ratio improvement of 100–150 basis points year over year. It reported ~159k members at the end of 3Q26 and offered no formal 2027 or 2028 guidance.

View
Proposed Sales
Value
$85.6K
Shares
19.3K
Filed
Oct 20, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Clover Health to Participate in U…
Published
Oct 26, 2026
View

Performance

5D 20D 120D MTD YTD
CLOV -22.8% -20.3% -3.8% -15.5% +60.4%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -17.3% -14.0% +1.8% -10.2% +55.5%

Capital returns

Buyback program · as of May 6, 2024
Authorized
$20.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1801170 CUSIP 18914F103 13F (30d) 233 filings 213 filers Visit website Investor relations